Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Reto Schwendener

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Living Beings

Anatomy

Disorders

Leukemia L1210

Procedures

Flow Cytometry

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
21
Schott, Herbert
9
Marty, Cornelia
8
Ballmer-Hofer, Kurt
6
Rentsch, Katharina
5
Odermatt, Bernhard
5
Hänseler, Edgar
4
Cattaneo-Pangrazzi, RM
4
Wunderli-Allenspach, Heidi
4
Zinkernagel, Rolf
4
Rubas, Werner
3
Sauter, C
3
Pasch, Thomas
3
Seiler, Peter
3
Schimmer, Ralph
3
Booy, Christa

Sign-in to see all Coauthors

Publications

TOP 3
Schott Herbert; Schott Sarah; Schwendener Reto A
Synthesis and in vitro activities of new anticancer duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding.
Sayi Ayca; Kohler Esther; Hitzler Iris; Arnold Isabelle; Schwendener Reto; Rehrauer Hubert; Müller Anne
The CD4+ T cell-mediated IFN-gamma response to Helicobacter infection is essential for clearance and determines gastric cancer risk.
Kataru Raghu P; Jung Keehoon; Jang Cholsoon; Yang Hanseul; Schwendener Reto A; Baik Jung Eun; Han Seung Hyun; Alitalo Kari; Koh Gou Young
Critical role of CD11b+ macrophages and VEGF in inflammatory lymphangiogenesis, antigen clearance, and inflammation resolution.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Reto Schwendener (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Schott Herbert; Schott Sarah; Schwendener Reto A
Synthesis and in vitro activities of new anticancer duplex drugs linking 2'-deoxy-5-fluorouridine (5-FdU) with 3'-C-ethynylcytidine (ECyd) via a phosphodiester bonding.
Bioorganic & medicinal chemistry 2009;17(19):6824-31.
2009: Sayi Ayca; Kohler Esther; Hitzler Iris; Arnold Isabelle; Schwendener Reto; Rehrauer Hubert; Müller Anne
The CD4+ T cell-mediated IFN-gamma response to Helicobacter infection is essential for clearance and determines gastric cancer risk.
Journal of immunology (Baltimore, Md. : 1950) 2009;182(11):7085-101.
2009: Kataru Raghu P; Jung Keehoon; Jang Cholsoon; Yang Hanseul; Schwendener Reto A; Baik Jung Eun; Han Seung Hyun; Alitalo Kari; Koh Gou Young
Critical role of CD11b+ macrophages and VEGF in inflammatory lymphangiogenesis, antigen clearance, and inflammation resolution.
Blood 2009;113(22):5650-9.
2009: Zumsteg Adrian; Baeriswyl Vanessa; Imaizumi Natsuko; Schwendener Reto; Rüegg Curzio; Christofori Gerhard
Myeloid cells contribute to tumor lymphangiogenesis.
PloS one 2009;4(9):e7067.
2008: Hippert Claire; Dubois Grégor; Morin Carole; Disson Olivier; Ibanes Sandy; Jacquet Chantal; Schwendener Reto; Antignac Corinne; Kremer Eric J; Kalatzis Vasiliki
Gene transfer may be preventive but not curative for a lysosomal transport disorder.
Molecular therapy : the journal of the American Society of Gene Therapy 2008;16(8):1372-81.
2008: Kim David D; Miwa Takashi; Kimura Yuko; Schwendener Reto A; van Lookeren Campagne Menno; Song Wen-Chao
Deficiency of decay-accelerating factor and complement receptor 1-related gene/protein y on murine platelets leads to complement-dependent clearance by the macrophage phagocytic receptor CRIg.
Blood 2008;112(4):1109-19.
2008: Kim Edy Y; Battaile John T; Patel Anand C; You Yingjian; Agapov Eugene; Grayson Mitchell H; Benoit Loralyn A; Byers Derek E; Alevy Yael; Tucker Jennifer; Swanson Suzanne; Tidwell Rose; Tyner Jeffrey W; Morton Jeffrey D; Castro Mario; Polineni Deepika; Patterson G Alexander; Schwendener Reto A; Allard John D; Peltz Gary; Holtzman Michael J
Persistent activation of an innate immune response translates respiratory viral infection into chronic lung disease.
Nature medicine 2008;14(6):633-40.
2008: Ren Weiping; Markel David C; Schwendener Reto; Ding Yunhong; Wu Bin; Wooley Paul H
Macrophage depletion diminishes implant-wear-induced inflammatory osteolysis in a mouse model.
Journal of biomedical materials research. Part A 2008;85(4):1043-51.
2008: Wang Jinghua; Barke Roderick A; Charboneau Richard; Schwendener Reto; Roy Sabita
Morphine induces defects in early response of alveolar macrophages to Streptococcus pneumoniae by modulating TLR9-NF-kappa B signaling.
Journal of immunology (Baltimore, Md. : 1950) 2008;180(5):3594-600.
2008: Jeon Bong-Hyun; Jang Cholsoon; Han Jinah; Kataru Raghu P; Piao Lianhua; Jung Keehoon; Cha Hye Ji; Schwendener Reto A; Jang Kyu Yun; Kim Kwan-Sik; Alitalo Kari; Koh Gou Young
Profound but dysfunctional lymphangiogenesis via vascular endothelial growth factor ligands from CD11b+ macrophages in advanced ovarian cancer.
Cancer research 2008;68(4):1100-9.
2008: Hauk Thomas G; Müller Adrienne; Lee Jieun; Schwendener Reto; Fischer Dietmar
Neuroprotective and axon growth promoting effects of intraocular inflammation do not depend on oncomodulin or the presence of large numbers of activated macrophages.
Experimental neurology 2008;209(2):469-82.
2008: Shen Wei; Li Yong; Zhu Jinhong; Schwendener Reto; Huard Johnny
Interaction between macrophages, TGF-beta1, and the COX-2 pathway during the inflammatory phase of skeletal muscle healing after injury.
Journal of cellular physiology 2008;214(2):405-12.
2008: Bijnsdorp I V; Schwendener R A; Schott H; Schott S; Fichtner I; Honeywell R J; Losekoot N; Laan A C; Peters G J
In vitro activity and mechanism of action of a duplex and multidrug of ethynylcytidine and 5-fluorodeoxyuridine.
Nucleic acids symposium series (2004) 2008;(52):651.
2007: Zehnder-Fjällman Ann H M; Marty Cornelia; Halin Cornelia; Hohn Alexander; Schibli Roger; Ballmer-Hofer Kurt; Schwendener Reto A
Evaluation of anti-VEGFR-3 specific scFv antibodies as potential therapeutic and diagnostic tools for tumor lymph-angiogenesis.
Oncology reports 2007;18(4):933-41.
2007: Cho Chung-Hyun; Koh Young Jun; Han Jinah; Sung Hoon-Ki; Jong Lee Hyuek; Morisada Tohru; Schwendener Reto A; Brekken Rolf A; Kang Guson; Oike Yuichi; Choi Tae-Saeng; Suda Toshio; Yoo Ook-Joon; Koh Gou Young
Angiogenic role of LYVE-1-positive macrophages in adipose tissue.
Circulation research 2007;100(4):e47-57.
2007: Schwendener Reto A
Liposomes in biology and medicine.
Advances in experimental medicine and biology 2007;620():117-28.
2007: Bijnsdorp Irene V; Schwendener Reto A; Schott Herbert; Fichtner Iduna; Smid Kees; Schott Sarah; Laan Adrie C; Peters Godefridus J
In vivo and in vitro activity and mechanism of action of the multidrug cytarabine-L-glycerylyl-fluorodeoxyuridine.
Nucleosides, nucleotides & nucleic acids 2007;26(10-12):1619-24.
2006: Frank James A; Wray Charlie M; McAuley Danny F; Schwendener Reto; Matthay Michael A
Alveolar macrophages contribute to alveolar barrier dysfunction in ventilator-induced lung injury.
American journal of physiology. Lung cellular and molecular physiology 2006;291(6):L1191-8.
2006: Zeisberger S M; Odermatt B; Marty C; Zehnder-Fjällman A H M; Ballmer-Hofer K; Schwendener R A
Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach.
British journal of cancer 2006;95(3):272-81.
2006: Lasbury Mark E; Durant Pamela J; Ray Chad A; Tschang Dennis; Schwendener Reto; Lee Chao-Hung
Suppression of alveolar macrophage apoptosis prolongs survival of rats and mice with pneumocystis pneumonia.
Journal of immunology (Baltimore, Md. : 1950) 2006;176(11):6443-53.
2006: Marty Cornelia; Langer-Machova Zuzana; Sigrist Sandra; Schott Herbert; Schwendener Reto A; Ballmer-Hofer Kurt
Isolation and characterization of a scFv antibody specific for tumor endothelial marker 1 (TEM1), a new reagent for targeted tumor therapy.
Cancer letters 2006;235(2):298-308.
2005: Tyner Jeffrey W; Uchida Osamu; Kajiwara Naohiro; Kim Edy Y; Patel Anand C; O'Sullivan Mary P; Walter Michael J; Schwendener Reto A; Cook Donald N; Danoff Theodore M; Holtzman Michael J
CCL5-CCR5 interaction provides antiapoptotic signals for macrophage survival during viral infection.
Nature medicine 2005;11(11):1180-7.
2005: Buchholz Julia; Kaser-Hotz Barbara; Khan Tania; Rohrer Bley Carla; Melzer Katja; Schwendener Reto A; Roos Malgorzata; Walt Heinrich
Optimizing photodynamic therapy: in vivo pharmacokinetics of liposomal meta-(tetrahydroxyphenyl)chlorin in feline squamous cell carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(20):7538-44.
2005: Beck-Schimmer Beatrice; Rosenberger Dorothea S; Neff Simona B; Jamnicki Marina; Suter Dominik; Fuhrer Thomas; Schwendener Reto; Booy Christa; Reyes Livia; Pasch Thomas; Schimmer Ralph C
Pulmonary aspiration: new therapeutic approaches in the experimental model.
Anesthesiology 2005;103(3):556-66.
2005: Probst H C; Tschannen K; Odermatt B; Schwendener R; Zinkernagel R M; Van Den Broek M
Histological analysis of CD11c-DTR/GFP mice after in vivo depletion of dendritic cells.
Clinical and experimental immunology 2005;141(3):398-404.
2005: Ludwig Peter S; Schwendener Reto A; Schott Herbert
Synthesis and anticancer activities of amphiphilic 5-fluoro-2'-deoxyuridylic acid prodrugs.
European journal of medicinal chemistry 2005;40(5):494-504.
2005: Robinson John A; Shankaramma Sasalu C; Jetter Peter; Kienzl Ursula; Schwendener Reto A; Vrijbloed Jan W; Obrecht Daniel
Properties and structure-activity studies of cyclic beta-hairpin peptidomimetics based on the cationic antimicrobial peptide protegrin I.
Bioorganic & medicinal chemistry 2005;13(6):2055-64.
2005: Rubio Demirovic Alma; Marty Cornelia; Console Sandra; Zeisberger Steffen M; Ruch Claudia; Jaussi Rolf; Schwendener Reto A; Ballmer-Hofer Kurt
Targeting human cancer cells with VEGF receptor-2-directed liposomes.
Oncology reports 2005;13(2):319-24.
2005: Beck-Schimmer Beatrice; Schwendener Reto; Pasch Thomas; Reyes Livia; Booy Christa; Schimmer Ralph C
Alveolar macrophages regulate neutrophil recruitment in endotoxin-induced lung injury.
Respiratory research 2005;6():61.
2005: Schwendener Reto; Schott Herbert
Lipophilic arabinofuranosyl cytosine derivatives in liposomes.
Methods in enzymology 2005;391():58-70.
2005: Marty Cornelia; Schwendener Reto A
Cytotoxic tumor targeting with scFv antibody-modified liposomes.
Methods in molecular medicine 2005;109():389-402.
2004: Engler Olivier B; Schwendener Reto A; Dai Wen Juan; Wölk Benno; Pichler Werner; Moradpour Darius; Brunner Thomas; Cerny Andreas
A liposomal peptide vaccine inducing CD8+ T cells in HLA-A2.1 transgenic mice, which recognise human cells encoding hepatitis C virus (HCV) proteins.
Vaccine 2004;23(1):58-68.
2004: Marty C; Meylan C; Schott H; Ballmer-Hofer K; Schwendener R A
Enhanced heparan sulfate proteoglycan-mediated uptake of cell-penetrating peptide-modified liposomes.
Cellular and molecular life sciences : CMLS 2004;61(14):1785-94.
2004: Storni Tazio; Ruedl Christiane; Schwarz Katrin; Schwendener Reto A; Renner Wolfgang A; Bachmann Martin F
Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects.
Journal of immunology (Baltimore, Md. : 1950) 2004;172(3):1777-85.
2003: Console Sandra; Marty Cornelia; García-Echeverría Carlos; Schwendener Reto; Ballmer-Hofer Kurt
Antennapedia and HIV transactivator of transcription (TAT) "protein transduction domains" promote endocytosis of high molecular weight cargo upon binding to cell surface glycosaminoglycans.
The Journal of biological chemistry 2003;278(37):35109-14.
2003: Aichele Peter; Zinke Jana; Grode Leander; Schwendener Reto A; Kaufmann Stefan H E; Seiler Peter
Macrophages of the splenic marginal zone are essential for trapping of blood-borne particulate antigen but dispensable for induction of specific T cell responses.
Journal of immunology (Baltimore, Md. : 1950) 2003;171(3):1148-55.
2003: Madjdpour C; Jewell U R; Kneller S; Ziegler U; Schwendener R; Booy C; Kläusli L; Pasch T; Schimmer R C; Beck-Schimmer B
Decreased alveolar oxygen induces lung inflammation.
American journal of physiology. Lung cellular and molecular physiology 2003;284(2):L360-7.
2002: Marty C; Odermatt B; Schott H; Neri D; Ballmer-Hofer K; Klemenz R; Schwendener R A
Cytotoxic targeting of F9 teratocarcinoma tumours with anti-ED-B fibronectin scFv antibody modified liposomes.
British journal of cancer 2002;87(1):106-12.
2002: Bueno Da Costa Maria Helena; Quintilio Wagner; Tanizaki Martha Massako; Sant'Anna Osvaldo Augusto; Schwendener Reto Albert; de Araujo Pedro Soares
Heat shock protein micro-encapsulation as a double tool for the improvement of new generation vaccines.
Journal of liposome research 2002;12(1-2):29-35.
2001: Seiler P; Schwendener R A; Bandermann S; Brinkmann V; Grode L; Kaufmann S H; Aichele P
Limited mycobacterial infection of the liver as a consequence of its microanatomical structure causing restriction of mycobacterial growth to professional phagocytes.
Infection and immunity 2001;69(12):7922-6.
2001: Roscic-Mrkic B; Schwendener R A; Odermatt B; Zuniga A; Pavlovic J; Billeter M A; Cattaneo R
Roles of macrophages in measles virus infection of genetically modified mice.
Journal of virology 2001;75(7):3343-51.
2001: Marty C; Scheidegger P; Ballmer-Hofer K; Klemenz R; Schwendener R A
Production of functionalized single-chain Fv antibody fragments binding to the ED-B domain of the B-isoform of fibronectin in Pichia pastoris.
Protein expression and purification 2001;21(1):156-64.
2001: Schwendener R A; Friedl K; Depenbrock H; Schott H; Hanauske A R
In vitro activity of liposomal N4octadecyl-1-beta-D-arabinofuranosylcytosine (NOAC), a new lipophilic derivative of 1-beta-D-arabinofuranocylcytosine on biopsized clonogenic human tumor cells and hematopoietic precursor cells.
Investigational new drugs 2001;19(3):203-10.
2000: Cattaneo-Pangrazzi R M; Schott H; Wunderli-Allenspach H; Derighetti M; Schwendener R A
Induction of cell cycle-dependent cytotoxicity and apoptosis by new heterodinucleoside phosphate dimers of 5-fluorodeoxyuridine in PC-3 human prostate cancer cells.
Biochemical pharmacology 2000;60(12):1887-96.
2000: Cattaneo-Pangrazzi R M; Schott H; Schwendener R A
The novel heterodinucleoside dimer 5-FdU-NOAC is a potent cytotoxic drug and a p53-independent inducer of apoptosis in the androgen-independent human prostate cancer cell lines PC-3 and DU-145.
The Prostate 2000;45(1):8-18.
2000: Ludewig B; Barchiesi F; Pericin M; Zinkernagel R M; Hengartner H; Schwendener R A
In vivo antigen loading and activation of dendritic cells via a liposomal peptide vaccine mediates protective antiviral and anti-tumour immunity.
Vaccine 2000;19(1):23-32.
2000: Horber D H; Cattaneo-Pangrazzi R M; von Ballmoos P; Schott H; Ludwig P S; Eriksson S; Fichtner I; Schwendener R A
Cytotoxicity, cell-cycle perturbations and apoptosis in human tumor cells by lipophilic N4-alkyl-1-beta-D-arabinofuranosylcytosine derivatives and the new heteronucleoside phosphate dimer arabinocytidylyl-(5'-->5')-N4-octadecyl-1-beta-D-arabinofuranosylcytosi ne.
Journal of cancer research and clinical oncology 2000;126(6):311-9.
2000: Cattaneo-Pangrazzi R M; Schott H; Wunderli-Allenspach H; Rothen-Rutishauser B; Guenthert M; Schwendener R A
Cell-cycle arrest and p53-independent induction of apoptosis in vitro by the new anticancer drugs 5-FdUrd-P-FdCydOct and dCydPam-P-FdUrd in DU-145 human prostate cancer cells.
Journal of cancer research and clinical oncology 2000;126(5):247-56.
1999: Ludewig B; Oehen S; Barchiesi F; Schwendener R A; Hengartner H; Zinkernagel R M
Protective antiviral cytotoxic T cell memory is most efficiently maintained by restimulation via dendritic cells.
Journal of immunology (Baltimore, Md. : 1950) 1999;163(4):1839-44.
1999: Koller-Lucae S K; Schott H; Schwendener R A
Low density lipoprotein and liposome mediated uptake and cytotoxic effect of N4-octadecyl-1-beta-D-arabinofuranosylcytosine in Daudi lymphoma cells.
British journal of cancer 1999;80(10):1542-9.
1999: Schwendener R A; Peghini P A; Ludwing P S; Schott H
Synthesis, in vitro anti-HIV and anti-hepatitis B activities and pharmacokinetic properties of amphiphilic heterodinucleoside phosphates containing ddC and AZT.
Nucleosides & nucleotides 1999;18(4-5):949-50.
1999: Koller-Lucae S K; Suter M J; Rentsch K M; Schott H; Schwendener R A
Metabolism of the new liposomal anticancer drug N4-octadecyl-1-beta-D-arabinofuranosylcytosine in mice.
Drug metabolism and disposition: the biological fate of chemicals 1999;27(3):342-50.
1998: van Borssum Waalkes M; Goris H; Dontje B H; Schwendener R A; Scherphof G; Nijhof W
Toxicity of liposomal 3'-5'-O-dipalmitoyl-5-fluoro-2'-deoxyuridine in mice.
Anti-cancer drug design 1998;13(4):291-305.
1998: Peghini P A; Zahner R; Kuster H; Schott H; Schwendener R A
In vitro anti-human immunodeficiency virus and anti-hepatitis B virus activities and pharmacokinetic properties of heterodinucleoside phosphates containing AZT or ddC.
Antiviral chemistry & chemotherapy 1998;9(2):117-26.
1998: Rentsch K M; Schwendener R A; Pestalozzi B C; Sauter C; Wunderli-Allenspach H; Hänseler E
Pharmacokinetic studies of mitoxantrone and one of its metabolites in serum and urine in patients with advanced breast cancer.
European journal of clinical pharmacology 1998;54(1):83-9.
1997: Rentsch K M; Schwendener R A; Schott H; Hänseler E
Pharmacokinetics of N4-octadecyl-1-beta-D-arabinofuranosylcytosine in plasma and whole blood after intravenous and oral administration to mice.
The Journal of pharmacy and pharmacology 1997;49(11):1076-81.
1997: Seiler P; Aichele P; Odermatt B; Hengartner H; Zinkernagel R M; Schwendener R A
Crucial role of marginal zone macrophages and marginal zone metallophils in the clearance of lymphocytic choriomeningitis virus infection.
European journal of immunology 1997;27(10):2626-33.
1997: Koller-Lucae S K; Schott H; Schwendener R A
Interactions with human blood in vitro and pharmacokinetic properties in mice of liposomal N4-octadecyl-1-beta-D-arabinofuranosylcytosine, a new anticancer drug.
The Journal of pharmacology and experimental therapeutics 1997;282(3):1572-80.
1997: Frankenberger M; Hofmann B; Emmerich B; Nerl C; Schwendener R A; Ziegler-Heitbrock H W
Liposomal 1,25 (OH)2 vitamin D3 compounds block proliferation and induce differentiation in myelomonocytic leukaemia cells.
British journal of haematology 1997;98(1):186-94.
1997: Rentsch K M; Horber D H; Schwendener R A; Wunderli-Allenspach H; Hänseler E
Comparative pharmacokinetic and cytotoxic analysis of three different formulations of mitoxantrone in mice.
British journal of cancer 1997;75(7):986-92.
1996: Schott H; Schwendener R A
Synthesis and structure-activity studies in vivo of liposomal phospholipid-N4-palmitoyl- and N4-hexadecyl-1-beta-D-arabinofuranosylcytosine conjugates.
Anti-cancer drug design 1996;11(6):451-62.
1996: Rentsch K M; Schwendener R A; Hänseler E
Determination of mitoxantrone in mouse whole blood and different tissues by high-performance liquid chromatography.
Journal of chromatography. B, Biomedical applications 1996;679(1-2):185-92.
1996: Schwendener R A; Schott H
Lipophilic 1-beta-D-arabinofuranosyl cytosine derivatives in liposomal formulations for oral and parenteral antileukemic therapy in the murine L1210 leukemia model.
Journal of cancer research and clinical oncology 1996;122(12):723-6.
1996: Schwendener R A; Horber D H; Odermatt B; Schott H
Oral antitumour activity in murine L1210 leukaemia and pharmacological properties of liposome formulations of N4-alkyl derivatives of 1-beta-D-arabinofuranosylcytosine.
Journal of cancer research and clinical oncology 1996;122(2):102-8.
1995: Rentsch K M; Schwendener R A; Schott H; Hänseler E
Sensitive high-performance liquid chromatographic method for the determination of N4-hexadecyl- and N4-octadecyl-1-beta-D-arabinofuranosylcytosine in plasma and erythrocytes.
Journal of chromatography. B, Biomedical applications 1995;673(2):259-66.
1995: Horber D H; von Ballmoos P; Schott H; Schwendener R A
Cell cycle-dependent cytotoxicity and induction of apoptosis by liposomal N4-hexadecyl-1-beta-D-arabinofuranosylcytosine.
British journal of cancer 1995;72(5):1067-73.
1995: Pestalozzi B C; Vass A; Adam H; Horber D H; Schwendener R A; Sauter C
Phase II study of liposome-complexed mitoxantrone in patients with advanced breast cancer.
European journal of cancer (Oxford, England : 1990) 1995;31A(6):1024.
1995: Horber D H; Schott H; Schwendener R A
Cellular pharmacology of a liposomal preparation of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine, a lipophilic derivative of 1-beta-D-arabinofuranosylcytosine.
British journal of cancer 1995;71(5):957-62.
1995: Horber D H; Ottiger C; Schott H; Schwendener R A
Pharmacokinetic properties and interactions with blood components of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine (NHAC) incorporated into liposomes.
The Journal of pharmacy and pharmacology 1995;47(4):282-8.
1995: Horber D H; Schott H; Schwendener R A
Cellular pharmacology of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine in the human leukemic cell lines K-562 and U-937.
Cancer chemotherapy and pharmacology 1995;36(6):483-92.
1994: Condrau M A; Schwendener R A; Zimmermann M; Muser M H; Graf U; Niederer P; Anliker M
Time-resolved flow cytometry for the measurement of lanthanide chelate fluorescence: II. Instrument design and experimental results.
Cytometry 1994;16(3):195-205.
1994: Condrau M A; Schwendener R A; Niederer P; Anliker M
Time-resolved flow cytometry for the measurement of lanthanide chelate fluorescence: I. Concept and theoretical evaluation.
Cytometry 1994;16(3):187-94.
1994: Schwendener R A; Gowland P; Horber D H; Zahner R; Schertler A; Schott H
New lipophilic alkyl/acyl dinucleoside phosphates as derivatives of 3'-azido-3'-deoxythymidine: inhibition of HIV-1 replication in vitro and antiviral activity against Rauscher leukemia virus infected mice with delayed treatment regimens.
Antiviral research 1994;24(1):79-93.
1992: Pfisterer M; Salamin P A; Schwendener R; Burkart F
Clinical risk assessment after first myocardial infarction--is additional noninvasive testing necessary?
Chest 1992;102(5):1499-506.
1992: Pestalozzi B; Schwendener R; Sauter C
Phase I/II study of liposome-complexed mitoxantrone in patients with advanced breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1992;3(6):445-9.
1992: Schwendener R A; Schott H
Treatment of L1210 murine leukemia with liposome-incorporated N4-hexadecyl-1-beta-D-arabinofuranosyl cytosine.
International journal of cancer. Journal international du cancer 1992;51(3):466-9.
1991: Schwendener R A; Fiebig H H; Berger M R; Berger D P
Evaluation of incorporation characteristics of mitoxantrone into unilamellar liposomes and analysis of their pharmacokinetic properties, acute toxicity, and antitumor efficacy.
Cancer chemotherapy and pharmacology 1991;27(6):429-39.
1990: Schwendener R A; Wüthrich R; Duewell S; Wehrli E; von Schulthess G K
A pharmacokinetic and MRI study of unilamellar gadolinium-, manganese-, and iron-DTPA-stearate liposomes as organ-specific contrast agents.
Investigative radiology 1990;25(8):922-32.
1990: Schwendener R A; Trüb T; Schott H; Langhals H; Barth R F; Groscurth P; Hengartner H
Comparative studies of the preparation of immunoliposomes with the use of two bifunctional coupling agents and investigation of in vitro immunoliposome-target cell binding by cytofluorometry and electron microscopy.
Biochimica et biophysica acta 1990;1026(1):69-79.
1989: Keller R; Keist R; Schwendener R A
Discrepancy in the abilities of lymphokines and bacteria to mediate tumor protection in vivo and/or tumoricidal activity by macrophages in vitro.
International journal of cancer. Journal international du cancer 1989;44(3):512-7.
1988: Schott H; Leitner B; Schwendener R A; Hengartner H
Chromatography of functionalized liposomes and their components.
Journal of chromatography 1988;441(1):115-24.
1988: Schott H; Seeling R; Hengartner H; Schwendener R A
Palmitoyl derivatives of L-cysteine, cysteamine, L-cystine, cystamine and their incorporation into the bilayers of unilamellar liposomes.
Biochimica et biophysica acta 1988;940(1):127-35.
1988: Schwendener R A
Incorporation of chlorpromazine into bilayer liposomes for protection against microsomal metabolism and liver absorption.
European journal of drug metabolism and pharmacokinetics 1988;13(2):135-41.
1988: Supersaxo A; Rubas W; Hartmann H R; Schott H; Hengartner H; Schwendener R A
The antitumour effect of lipophilic derivatives of 5-fluoro-2'-deoxyuridine incorporated into liposomes.
Journal of microencapsulation 1988;5(1):1-11.
1987: Schwendener R A; Schott H; Hartmann H R; Supersaxo A; Rubas W; Hengartner H
[Liposomes as carriers of lipophilic cytosine arabinoside and fluorodeoxyuridine derivatives. Their cytostatic effect and possibilities of tumor cell specific therapy]
Onkologie 1987;10(4):232-9.
1986: Rubas W; Supersaxo A; Weder H G; Hartmann H R; Hengartner H; Schott H; Schwendener R
Treatment of murine L1210 lymphoid leukemia and melanoma B16 with lipophilic cytosine arabinoside prodrugs incorporated into unilamellar liposomes.
International journal of cancer. Journal international du cancer 1986;37(1):149-54.
1986: Marcus M M; Apell H J; Roudna M; Schwendener R A; Weder H G; Läuger P
(Na+ + K+)-ATPase in artificial lipid vesicles: influence of lipid structure on pumping rate.
Biochimica et biophysica acta 1986;854(2):270-8.
1986: Schwendener R A
The preparation of large volumes of homogeneous, sterile liposomes containing various lipophilic cytostatic drugs by the use of a capillary dialyzer.
Cancer drug delivery 1986;3(2):123-9.
1985: Schwendener R A; Supersaxo A; Rubas W; Weder H G; Hartmann H R; Schott H; Ziegler A; Hengartner H
5'-O-Palmitoyl- and 3',5'-O-dipalmitoyl-5-fluoro-2'-deoxyuridine--novel lipophilic analogues of 5'-fluoro-2'-deoxyuridine: synthesis, incorporation into liposomes and preliminary biological results.
Biochemical and biophysical research communications 1985;126(2):660-6.
1984: Schwendener R A; Lagocki P A; Rahman Y E
The effects of charge and size on the interaction of unilamellar liposomes with macrophages.
Biochimica et biophysica acta 1984;772(1):93-101.
1981: Schwendener R A; Asanger M; Weder H G
n-Alkyl-glucosides as detergents for the preparation of highly homogeneous bilayer liposomes of variable sizes ( 60-240 nm phi) applying defined rates of detergent removal by dialysis.
Biochemical and biophysical research communications 1981;100(3):1055-62.
1978: Milsmann M H; Schwendener R A; Weder H G
The preparation of large single bilayer liposomes by a fast and controlled dialysis.
Biochimica et biophysica acta 1978;512(1):147-55.
1978: Schwendener R A; Weder H G
The binding of chlorpromazine to bilayer liposomes. Evaluation of stoichiometric constants from equilibrium and steady state studies.
Biochemical pharmacology 1978;27(23):2721-7.

Sign-in to see more